Skip to Content
 
Daniel A.  Barocas

Daniel A. Barocas, M.D., M.P.H.

Associate Professor of Surgery
Associate Professor of Medicine
Urologic Surgeon/Oncologist

Profile

Dr. Barocas received his medical degree in 2001 at the Johns Hopkins University School of Medicine and went on to complete a residency in urology (2007) at the New York Presbyterian Hospital-Weill Cornell Medical Center.  He came to Vanderbilt University Medical Center in 2007, where he completed a 2-year fellowship in urologic oncology and a master of public health degree.
Read more...

Dr. Barocas received his medical degree in 2001 at the Johns Hopkins University School of Medicine and went on to complete a residency in urology (2007) at the New York Presbyterian Hospital-Weill Cornell Medical Center.  He came to Vanderbilt University Medical Center in 2007, where he completed a 2-year fellowship in urologic oncology and a master of public health degree.  He was awarded a training grant from the National Institutes of Environmental Health Sciences to fund his masters program and masters thesis on prostate cancer risk factors.

Dr. Barocas' clinical interest is the surgical treatment of genitourinary (GU) cancers, including prostate, bladder, kidney, penile, testicular and urethral cancers.  He is experienced in open and laparoscopic surgery and is a leader in robotic surgery for genitourinary cancers. 

Dr. Barocas is a strong patient advocate who partners with patients and families to treat the cancer while preserving quality of life.  His research interest is in measuring outcomes and improving the quality of surgical care for GU cancers. Dr. Barocas oversees the department of urologic surgery cancer research databases and guides research on a number of important topics, such as comparative studies on outcomes and measures of effectiveness for open versus robotic surgical procedures in the treatment of prostate and bladder cancers. Dr. Barocas also performs research in large national datasets, in an effort to identify and address variation in the quality of care for GU cancers and to assess the diffusion of new treatments (such as robotics) in the community.  

Dr. Barocas' experience as a clinician and training as a researcher qualify him to serve in leadership positions in academic urology and inform his research program.  He serves on several national committees, including the American Urological Association (AUA) guidelines panel for the development of standards for evaluating patients with suspected bladder cancer and the prostate cancer early detection guidelines panel for the National Comprehensive Cancer Network (NCCN.)  In 2007 and 2008, he was awarded the American Society of Clinical Oncology (ASCO) Foundation Merit Award for his commitment and contributions to notable research in GU cancers.  Dr. Barocas is a reviewer for AUA educational materials as well as professional publications, including Urology and British Journal of Urology International. In 2008, he was named Best Reviewer of Manuscripts in Bladder and Kidney Cancer by the Journal of Urology. He is a frequent invited speaker and lecturer on topics related to his work in urologic oncology. He has authored more than 100 abstracts, book chapters, letters, posters, videos and articles which were published in peer-reviewed journals, including Urologic Oncology and Cancer. He is a member of the AUA, the Society of Urologic Oncology, the Vanderbilt Urology Society, the Vanderbilt-Ingram Cancer Center, Vanderbilt's Center for Surgical Quality and Outcomes Research, and the Elliott Newman Society at VUMC.

Education
  • M.P.H., Vanderbilt University, Nashville, Tennessee (2010)
  • M.D., Johns Hopkins University, Baltimore, Maryland (2001)
  • B.A., University of Pennsylvania, Philadelphia, Pennsylvania (1992)
  • B.S.E., University of Pennsylvania, Philadelphia, Pennsylvania (1992)
  • Fellowship - Vanderbilt University Medical Center (2008)
  • Residency - New York Presbyterian Hospital (2007)
  • Internship - New York Presbyterian Hospital (2003)
  • Residency - New York Presbyterian Hospital (2003)
Publications
  • Morgan TM, Tang D, Stratton KL, Barocas DA, Anderson CB, Gregg JR, Chang SS, Cookson MS, Herrell SD, Smith JA, Clark PE. Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur. Urol [print-electronic]. 2011 Jun; 59(6): 923-8. PMID: 21295907, PMCID: PMC3085569, PII: S0302-2838(11)00055-8, DOI: 10.1016/j.eururo.2011.01.034, ISSN: 1873-7560.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21295907.
  • Fowke JH, Motley SS, Barocas DA, Cookson MS, Concepcion R, Byerly S, Smith JA. The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer. Cancer Causes Control [print-electronic]. 2011 Mar; 22(3): 417-26. PMID: 21170754, PMCID: PMC3042514, DOI: 10.1007/s10552-010-9713-4, ISSN: 1573-7225.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21170754.
  • Thompson IM, Salem S, Chang SS, Clark PE, Davis R, Herrell SD, Kordan Y, Baumgartner R, Phillips S, Smith JA, Cookson MS, Barocas DA. Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: a tale of two methods. World J Urol [print-electronic]. 2011 Feb; 29(1): 15-20. PMID: 21079968, DOI: 10.1007/s00345-010-0611-x, ISSN: 1433-8726.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21079968.
  • Aghazadeh MA, Barocas DA, Salem S, Clark PE, Cookson MS, Davis R, Gregg J, Stimson CJ, Smith JA, Chang SS. Determining factors for hospital discharge status after radical cystectomy in a large contemporary cohort. J. Urol [print-electronic]. 2011 Jan; 185(1): 85-9. PMID: 21074199, PII: S0022-5347(10)04269-2, DOI: 10.1016/j.juro.2010.08.016, ISSN: 1527-3792.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21074199.
  • Gregg JR, Cookson MS, Phillips S, Salem S, Chang SS, Clark PE, Davis R, Stimson CJ, Aghazadeh M, Smith JA, Barocas DA. Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. J. Urol [print-electronic]. 2011 Jan; 185(1): 90-6. PMID: 21074802, PMCID: PMC3049248, PII: S0022-5347(10)04557-X, DOI: 10.1016/j.juro.2010.09.021, ISSN: 1527-3792.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21074802.
  • Salem S, Mitchell RE, El-Alim El-Dorey A, Smith JA, Barocas DA. Successful control of schistosomiasis and the changing epidemiology of bladder cancer in Egypt. BJU Int [print-electronic]. 2011 Jan; 107(2): 206-11. PMID: 21208365, DOI: 10.1111/j.1464-410X.2010.09622.x, ISSN: 1464-410X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21208365.
  • Kordan Y, Barocas DA, Altamar HO, Clark PE, Chang SS, Davis R, Herrell SD, Baumgartner R, Mishra V, Chan RC, Smith JA, Cookson MS. Comparison of transfusion requirements between open and robotic-assisted laparoscopic radical prostatectomy. BJU Int [print-electronic]. 2010 Oct; 106(7): 1036-40. PMID: 20151960, PII: BJU9233, DOI: 10.1111/j.1464-410X.2010.09233.x, ISSN: 1464-410X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20151960.
  • Salem S, Chang SS, Clark PE, Davis R, Herrell SD, Kordan Y, Wills ML, Shappell SB, Baumgartner R, Phillips S, Smith JA, Cookson MS, Barocas DA. Comparative analysis of whole mount processing and systematic sampling of radical prostatectomy specimens: pathological outcomes and risk of biochemical recurrence. J. Urol [print-electronic]. 2010 Oct; 184(4): 1334-40. PMID: 20723932, PII: S0022-5347(10)03815-2, DOI: 10.1016/j.juro.2010.06.041, ISSN: 1527-3792.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20723932.
  • Stimson CJ, Chang SS, Barocas DA, Humphrey JE, Patel SG, Clark PE, Smith JA, Cookson MS. Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J. Urol [print-electronic]. 2010 Oct; 184(4): 1296-300. PMID: 20723939, PII: S0022-5347(10)03779-1, DOI: 10.1016/j.juro.2010.06.007, ISSN: 1527-3792.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20723939.
  • Newton MR, Phillips S, Chang SS, Clark PE, Cookson MS, Davis R, Fowke JH, Herrell SD, Baumgartner R, Chan R, Mishra V, Blume JD, Smith JA, Barocas DA. Smaller prostate size predicts high grade prostate cancer at final pathology. J. Urol. 2010 Sep; 184(3): 930-7. PMID: 20643423, PII: S0022-5347(10)03517-2, DOI: 10.1016/j.juro.2010.04.082, ISSN: 1527-3792.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20643423.
  • Barocas DA, Chang SS. Penile cancer: clinical presentation, diagnosis, and staging. Urol. Clin. North Am. 2010 Aug; 37(3): 343-52. PMID: 20674691, PII: S0094-0143(10)00023-6, DOI: 10.1016/j.ucl.2010.04.002, ISSN: 1558-318X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20674691.
  • Barocas DA, Penson DF. Racial variation in the pattern and quality of care for prostate cancer in the USA: mind the gap. BJU Int [print-electronic]. 2010 Aug; 106(3): 322-8. PMID: 20553251, PMCID: PMC2910169, PII: BJU9467, DOI: 10.1111/j.1464-410X.2010.09467.x, ISSN: 1464-410X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20553251.
  • Barocas DA, Mitchell R, Chang SS, Cookson MS. Impact of surgeon and hospital volume on outcomes of radical prostatectomy. Urol. Oncol [print-electronic]. 2010 May; 28(3): 243-50. PMID: 19395287, PII: S1078-1439(09)00074-X, DOI: 10.1016/j.urolonc.2009.03.001, ISSN: 1873-2496.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19395287.
  • Stimson CJ, Cookson MS, Barocas DA, Clark PE, Humphrey JE, Patel SG, Smith JA, Chang SS. Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. J. Urol [print-electronic]. 2010 May; 183(5): 1732-7. PMID: 20299043, PII: S0022-5347(10)00029-7, DOI: 10.1016/j.juro.2010.01.028, ISSN: 1527-3792.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20299043.
  • Barocas DA, Salem S, Kordan Y, Herrell SD, Chang SS, Clark PE, Davis R, Baumgartner R, Phillips S, Cookson MS, Smith JA. Robotic assisted laparoscopic prostatectomy versus radical retropubic prostatectomy for clinically localized prostate cancer: comparison of short-term biochemical recurrence-free survival. J. Urol [print-electronic]. 2010 Mar; 183(3): 990-6. PMID: 20083261, PII: S0022-5347(09)02906-1, DOI: 10.1016/j.juro.2009.11.017, ISSN: 1527-3792.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20083261.
  • Barocas DA. Editorial comment [editorial]. J. Urol [print-electronic]. 2010 Jan; 183(1): 143-4. PMID: 19913807, PII: S0022-5347(09)02635-4, DOI: 10.1016/j.juro.2009.08.206, ISSN: 1527-3792.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19913807.
  • Kordan Y, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Herrell SD, Baumgartner R, Phillips S, Smith JA, Barocas DA. Impact of positive apical surgical margins on likelihood of biochemical recurrence after radical prostatectomy. J. Urol. 2009 Dec; 182(6): 2695-701. PMID: 19836759, PII: S0022-5347(09)02076-X, DOI: 10.1016/j.juro.2009.08.054, ISSN: 1527-3792.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19836759.
  • Kordan Y, Chang SS, Salem S, Cookson MS, Clark PE, Davis R, Herrell SD, Baumgartner R, Phillips S, Smith JA, Barocas DA. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy. J. Urol [print-electronic]. 2009 Nov; 182(5): 2291-5. PMID: 19758638, PII: S0022-5347(09)01744-3, DOI: 10.1016/j.juro.2009.07.020, ISSN: 1527-3792.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19758638.
  • Mitchell RE, Lee BT, Cookson MS, Barocas DA, Herrell SD, Clark PE, Smith JA, Chang SS. Immediate surgical outcomes for radical prostatectomy in the University HealthSystem Consortium Clinical Data Base: the impact of hospital case volume, hospital size and geographical region on 48,000 patients. BJU Int [print-electronic]. 2009 Nov; 104(10): 1442-5. PMID: 19681895, PII: BJU8794, DOI: 10.1111/j.1464-410X.2009.08794.x, ISSN: 1464-410X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19681895.